GlaxoSmithKline Offers Vaccine Booster to Research Groups
February 02 2020 - 7:41PM
Dow Jones News
By Denise Roland
Vaccines giant GlaxoSmithKline PLC said Monday it would donate a
vaccine-booster to groups racing to develop a shot against the new
coronavirus.
Glaxo has developed a so-called adjuvant, which it uses in its
seasonal flu shot, that can make a vaccine more effective, meaning
that smaller doses are needed to achieve immunity.
Glaxo is working with the Coalition for Epidemic Preparedness
Innovations, the Norwegian nonprofit that is funding several of the
groups trying to develop a new vaccine.
One of those groups, the University of Queensland, said it will
use the Glaxo adjuvant as it develops its candidate vaccine.
CEPI Chief Executive Richard Hatchett said Glaxo's contribution
has the potential to make more vaccine available more rapidly, by
making a given supply of vaccine go farther and increasing the
number of people who can benefit.
(END) Dow Jones Newswires
February 02, 2020 19:26 ET (00:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024